Question 1

What is GLP-1?

Accepted Answer

GLP-1 (glucagon-like peptide-1) is something your own body already makes. A 2025 review describes the two gut-derived incretin hormones, GIP and GLP-1, as playing a crucial role in glycemic control. Incretin means a hormone the intestine releases once food arrives, and glycemic means relating to blood sugar. A 2025 review of weight-loss mechanisms sets out the peripheral side of it: enhancing insulin secretion, reducing glucagon release, delaying gastric emptying, and regulating gut hormones. Gastric emptying is the speed at which the stomach passes food along. So the hormone is a signal rather than a medicine. The medicines came later, built to hold that signal in place far longer than the body does.

Question 2

Is GLP-1 a hormone or a group of medicines?

Accepted Answer

Both, and that ambiguity is built into the way people search for it. The hormone is GLP-1. A medicine that switches on the same receptor is a GLP-1 receptor agonist, shortened to GLP-1RA, and agonist means something that turns a receptor on. That shorthand is why three letters cover a hormone and a pharmacy shelf at once. A 2025 review of real-world use puts it in plain words: GLP-1RAs, like liraglutide, semaglutide, and tirzepatide, help manage weight by mimicking hormones that control blood sugar and appetite. Mimicking is the operative word, because these are engineered copies rather than the hormone itself. The distinction decides how a label should be read. A bottle offering to support the body's own GLP-1 makes a claim about the hormone, and a prescription naming a receptor agonist is a different category of thing.

Question 3

Which molecules are in the GLP-1 class?

Accepted Answer

The class is wider than the two names most people know. A 2019 meta-analysis of cardiovascular outcome trials set out seven of them by trial name: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide). That is six molecules, plus a tablet made from one of them. Three of those are the ones people actually ask about. A 2025 review of real-world use names the currently approved GLP-1RA-based weight-loss therapies, that is, liraglutide, semaglutide and tirzepatide. Semaglutide, tirzepatide and retatrutide each have a page of their own on this site, carrying their own trial figures and their own approval status. This one points at them rather than saying it all over again. What actually separates one member of this class from another is taken apart at the GLP-1 comparison page.

Question 4

Are all GLP-1 medicines peptides?

Accepted Answer

No, and the newest ones are not peptides at all. A 2023 trial describes the nonpeptide glucagon-like peptide-1 receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. Nonpeptide means a small chemical built from scratch, not a chain of amino acids. That matters for anyone treating peptide as a synonym for this whole category. A 2025 phase 3 report calls it orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 receptor agonist. A 2022 review of diabetes therapy notes that this has already been achieved for incretins, while there are still some challenges for the oral application of insulin. So the word peptide describes how some of these molecules are assembled. It is not what the class is defined by, and it says nothing about what sits inside any particular container.

Question 5

How is every approved GLP-1 medicine given?

Accepted Answer

Two ways, and only two, across the published trials. Most of them go in with a needle under the skin. A 2024 network meta-analysis compared s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus, where s.c. is short for subcutaneous, meaning the layer of fat just under the skin. How often a shot is given depends on the molecule, not the route. One 2024 trial randomly assigned participants to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week, while a Copenhagen programme ran once-daily subcutaneous liraglutide 3.0 mg against exercise and placebo. The other way in is a swallowed tablet. A 2019 phase 3 trial randomised adults with type 2 diabetes to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo, and a 2025 review records the availability of both subcutaneous and oral formulations. Those are the only two routes in the work behind this page. The amounts and schedules each molecule was given on are set out at the GLP-1 dosage page.

Question 6

Are GLP-1 pills a real thing?

Accepted Answer

Yes, and this is where one phrase covers two completely different objects. The first is a prescription tablet. A 2019 trial tested the first oral glucagon-like peptide 1 receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes, and the 703 patients randomized make it a substantial piece of work rather than a pilot. The regulator counts that tablet among approved medicines. The Food and Drug Administration's Adverse Event Reporting System database was queried for events related to exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023. Being counted from one year after approval is a statement about regulatory status, not about how well anything works. What that approval covers is one tablet dispensed on prescription. It does not travel to anything else sold under the same three letters, and the trial figures for that tablet belong on the semaglutide page.

Question 7

What about capsules sold as GLP-1 supplements?

Accepted Answer

This is the other object sharing the phrase, and the honest answer is short. No study among the research behind this page tests a capsule sold over the counter as a GLP-1 pill, a GLP-1 booster or a GLP-1 support blend. Not one of them examines a capsule of that kind, in any population, for any outcome. Read that carefully, because an absence of measurement is not a verdict on effectiveness. It does not establish that those capsules do nothing, nor that they do something. It says the question has not been asked in the published work this page is built on, which is a materially different statement. What the record holds instead is prescription molecules examined at considerable scale. A 2024 systematic review of randomised trials in type 2 diabetes reports that a total of 28 trials with 23,622 participants were included. A bottle borrowing the name of a pharmaceutical class does not borrow those trial results with it.

Question 8

Is there a GLP-1 patch?

Accepted Answer

Nothing in the published record behind this page describes one. Every route reported in the studies behind this page is an injection under the skin or a tablet taken by mouth. No study among the research behind this page delivers a GLP-1 receptor agonist through the skin, and none measures what happens when somebody tries. The scale of that injection-only record is worth a number. One cardiovascular outcomes trial randomized 1:1 to once weekly subcutaneous injection of either tirzepatide up to 15 mg or dulaglutide 1.5 mg, and over 2 years, 13,299 people at 640 sites in 30 countries across all world regions were randomized. So this is not a finding that patches fail, because no trial behind this page has tested that route. The question has not been asked in this literature at all. Every weight and blood-sugar figure attached to this class came from a weekly injection or a daily tablet, and those numbers describe what was given rather than a route nobody measured.

Question 9

What is this class approved to do?

Accepted Answer

Approval here is granted molecule by molecule and use by use, and it is never granted to a class as a whole. A 2025 review of real-world use names liraglutide, semaglutide and tirzepatide as the currently approved GLP-1RA-based weight-loss therapies. Approval for weight is a separate decision from approval for blood sugar, and the two arrived at different times. Not everything carrying the class name has an approval behind it. A 2025 phase 3 report places orforglipron in clinical development for type 2 diabetes and weight management, and in clinical development is not the same thing as approved. The list also moves over time. A 2022 review was written while tirzepatide was currently under review for marketing approval, and it now sits among the three named above. So anything written about approval in this class carries a date, and that date is part of the fact.

Question 10

How much human testing stands behind this class?

Accepted Answer

A great deal, and the aggregate is the point rather than any single trial. A 2019 systematic review of cardiovascular outcome trials reports that seven trials, with a combined total of 56 004 participants, were included. That is a scale almost nothing else on this site approaches. The comparisons between class members are large as well. The 2024 network meta-analysis in adults with type 2 diabetes drew on 28 trials with 23,622 participants, built to measure two molecules against each other rather than against nothing. Testing has also reached children. A 2025 trial in youth-onset type 2 diabetes was run as a multicentre (39 sites), multinational (eight countries) study, and the participants randomised had a mean age 14·7 years. A class this heavily studied still leaves the questions elsewhere on this page open.

Question 11

What did the heart and kidney trials find?

Accepted Answer

This is the strongest class-level result in the record, and it did not come from weight. A 2019 meta-analysis of seven placebo-controlled trials in patients with type 2 diabetes reports that GLP-1 receptor agonist treatment reduced MACE by 12%. MACE means major adverse cardiovascular events: cardiovascular death, stroke or heart attack counted together. The same analysis looked past the heart. Its authors concluded that treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes. Read the population before the percentage. Every participant in those seven trials had type 2 diabetes, so this is a finding about people with diabetes rather than about everybody in this class. Whether it holds for somebody without diabetes is a different question, and those trials did not ask it.

Question 12

Does a GLP-1 do the work on its own?

Accepted Answer

One trial in Copenhagen asked exactly that, and the answer is the most useful thing in this record. During an 8-week low-calorie diet (800 kcal/day), 195 adults with obesity and without diabetes lost 12% in body weight, and were then randomised to placebo, exercise, liraglutide, or the two combined for a year. Bone was one of the things they looked at. In that trial, liraglutide treatment alone reduced BMD at clinically relevant sites more than exercise alone despite similar weight loss, and BMD is short for bone mineral density. How fit people got was another. A 2026 secondary analysis of the same participants reports that exercise alone led to similar benefits, whereas liraglutide alone did not improve physical fitness. That is a statement about what a medicine does not do, measured against a comparison arm most trials never run.

Question 13

Does the weight come back after stopping?

Accepted Answer

The one randomised study in this record that followed people after treatment ended found that it largely does. In the year afterwards, weight regain was 6.0 kg larger after termination of liraglutide compared with after termination of supervised exercise, which compares two routes to the same weight loss. The combination held on better than either one alone. More participants who had previously received combination treatment maintained a weight loss of at least 10% of initial body weight one year after treatment termination than participants who had previously received placebo. Take the size of it honestly. In all, 109 participants attended the post-treatment study, and they were on one of the older molecules in this class. It is a real result from a trial rather than a guess at what probably happens, and it is not a measure of what the newer agents do once a person stops.

Question 14

What is documented about side effects?

Accepted Answer

The short version is here; the full detail is on the safety page. A 2025 review of real-world evidence reports frequent gastrointestinal disturbances in GLP-1RA users, as also observed in trials. The same review found no clear increase in risks of severe events like pancreatitis or pancreatic cancer, thyroid disorders, or depression and self-harm. A national reporting database shows a different picture. The number of AEs reported from all drugs within this study totaled 9,746. AEs means adverse events, anything bad somebody linked to a medicine. Medullary thyroid carcinoma and papillary thyroid carcinoma had the highest signals and were significant in virtually all medications. Those two pictures sit oddly side by side, and both belong in the record. A voluntary database counts what somebody chose to report. A review of real-world studies counts what was measured against a control group. The safety page takes them apart.

Question 15

What comes after GLP-1 on its own?

Accepted Answer

The direction of travel is adding a second or third receptor to one molecule. A 2025 review points to emerging dual and triple co-agonists, targeting GLP-1 alongside glucose-dependent insulinotropic polypeptide, and glucagon pathways. Those are three separate gut and pancreas hormones, and the idea is to pull more than one lever. One triple agonist has already reached people. A 2022 report describes LY3437943 as a novel triple agonist peptide at the glucagon receptor, the GIP receptor and the GLP-1 receptor. In obese mice, administration of LY3437943 decreased body weight and improved glycemic control, and a phase 1 study in people followed that work. A different pairing adds a hormone from outside the class. A 2024 article describes cagrilintide as an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide. Dual and triple agonists both have pages of their own on this site.

Question 16

How does GLP-1 actually work?

Accepted Answer

The hormone acts in two places at once, and the medicines were designed to copy both. A 2025 review of weight-loss mechanisms reports that centrally, GLP-1 RAs modulate brain regions controlling appetite, influencing neurotransmitter and peptide release to regulate hunger and energy expenditure. Centrally means in the brain, as opposed to out in the body. The second site is the gut and the pancreas, where the hormone starts. Glucagon is the hormone that pushes blood sugar up, so damping it works in the same direction as raising insulin. A 2020 review names the limit built into that design. Dose-related gastrointestinal effects limit efficacy, which is the constraint that pushed developers toward a second receptor rather than pushing the first one harder.

GLP-1